<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424616</url>
  </required_header>
  <id_info>
    <org_study_id>NAcDBSORP</org_study_id>
    <nct_id>NCT03424616</nct_id>
  </id_info>
  <brief_title>Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention</brief_title>
  <official_title>Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention:A Multicenter Randomized Double-Blind Sham-stimulation Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Dependence, Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tang-Du Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nucleus accumbens plays important roles in the process of opiate addiction and initial of
      relapse after detoxification.According to the single-centered preliminary open-labeled
      prospective trial results, the investigators hypothesize that bilateral stimulation of the
      NAc will effectively reduce the relapse of the opiate dependence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 6, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stagger-on design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The abstinent rate at 25 weeks after DBS stimulation on （Urine Tests）</measure>
    <time_frame>At 25 weeks after DBS stimulation on</time_frame>
    <description>If the participants or their families report no less than 2 times of the drug use in each of two consecutive weeks, or the consecutive 2 times of urine tests showed positive, or lost of follow-up, the case was defined as relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total days of abstinence for participants</measure>
    <time_frame>Baseline (preoperative), 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>The total days of abstinence for participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The longest duration for sustained abstinence for participants</measure>
    <time_frame>Baseline (preoperative), 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>The longest duration for sustained abstinence for participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale (VAS) craving score for opioid drugs</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Ranging from 0-10,with 0 indicates no craving while 10 indicates extreme craving</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight for participants</measure>
    <time_frame>Baseline (preoperative), 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Body weight for participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale（HAMD-17)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>17 items,Total scores&lt;7: normal;7&lt;Total scores&lt;17:possible depression;17&lt;Total scores&lt;24:definite depression;Total score&gt;24: severe depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaling for Opiate withdrawal symptoms</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>There were 19 items for rating 19 withdrawl symptoms, with 0 indicating none and 4 indicating most severe, the total scores are obtained by summary for scores of each items, ranging from 0-76, the higher the total scores indicating the worsen opiate withdrawl symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation on MATRICS-test</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Software system constructed by MATRICS company, which was used for evaluate the cognitive function of the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of positive urine test results</measure>
    <time_frame>Baseline (preoperative), 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>times of positive urine test/ total times of urine test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Scale (HAMA)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>14 items, Total scores&lt;6: normal;7&lt;Total scores&lt;14:possible anxiety;14&lt;Total scores&lt;21:definite anxiety;Total score&gt;21: severe anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh sleep quality index(PSQI)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Scaling for evaluating the sleep quality, the higher total scores indicating the more difficulties on sleep, thus the higher total scores indicating the worsen sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagerstrom Test Nicotine Dependence assessment (FTND)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Scaling for Nicotine Dependence: The higher of scores indicating higher lever of Nicotine Dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Disability Screening Schedule (SDSS)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Scaling for Social Disability with 10 items, the higher total scores indicating the much severe social disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of Daily Living Scale (ADL)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Consists of Physical Self－maintenance Scale and Instrumental Activities of Daily Living Scale, ranging from 0-56, total scores &lt;14, normal; total score &gt;14, ADL dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline (preoperative), 1week, 4 weeks, 12 weeks, 25 week after DBS stimulation on</time_frame>
    <description>Scaling for Quality of life with 8 subscales, the higher total scores indicating the better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Addiction</condition>
  <arm_group>
    <arm_group_label>Postoperative immediate Deep brain stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative delayed Deep brain stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Suzhou Sceneray® DBS System</intervention_name>
    <description>We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.</description>
    <arm_group_label>Postoperative immediate Deep brain stimulation</arm_group_label>
    <arm_group_label>Postoperative delayed Deep brain stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old &lt; Age &lt; 50 years old

          -  Moderate to severe opiates abuse disorders (fulfilled diagnostic-criteria according to
             DSM-5)

               1. History of opiates abuse no less than 3 years

               2. Failure of at least three addiction treatments ( in hospital or compulsive
                  rehabilitation）, among which failure of methadone maintenance treatment must be
                  met

               3. completion of detoxification ( Negative urine test for morphine, methamphetamine,
                  ketamine and buprenorphine)

          -  Free patient's decision/informed Consent (existing comprehensive ability in meaning,
             methodology and execution of the study and ability of acceptance, known the benefit
             and risk of the treatment)

        Exclusion Criteria:

          -  Clinical relevant psychiatric comorbidity (schizophrenic psychoses, bipolar affective
             diseases, severe personality disorder)

          -  Contraindications of a MRI-examination, e.g. implanted cardiac pacemaker/heart
             defibrillator

          -  Abuse of other type of drugs

          -  severe cognitive impairments

          -  Enrollment in other clinical trials

          -  Stereotactic respectively neurosurgical intervention in the past

          -  Contraindications of a stereotactic operation, e.g. increased bleeding-disposition,
             cerebrovascular diseases (e.g. arteriovenous malfunction, aneurysms, systemic vascular
             diseases)

          -  Serious and instable organic diseases (e.g. instable coronal heart disease)

          -  tested positively for HIV

          -  pregnancy and/or lactation

          -  Severe disorders for coagulation and liver function

          -  Epilepsy or other severe brain trauma or neurological impairments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guodong Gao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of neurosurgery, Tangdu Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Lu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Dependence, Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guodong Gao, M.D.</last_name>
    <phone>+86 29 84717556</phone>
    <email>gguodong@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Lu, M.D.</last_name>
    <phone>+86 13801027748</phone>
    <email>linlu@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute on Drug Dependence, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Lu, M.D.</last_name>
      <phone>+86 13801027748</phone>
      <email>linlu@bjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jie Shi, M.D.</last_name>
      <phone>+86 13910710407</phone>
    </contact_backup>
    <investigator>
      <last_name>Lin Lu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaijun Yang, M.D.</last_name>
      <phone>+86 13380082493</phone>
    </contact>
    <investigator>
      <last_name>Kaijun Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of neurosurgery, Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guodong Gao, M.D.</last_name>
      <phone>+86 29 84717556</phone>
      <email>gguodong@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xuelian Wang, M.D.</last_name>
      <phone>+86 29 84777284</phone>
      <email>wxlian@fmmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Guodong Gao, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xuelian Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bomin Sun, M.D.</last_name>
      <phone>+86 13817777401</phone>
      <email>bominsun@sh163a.sta.net.cn</email>
    </contact>
    <investigator>
      <last_name>Bomin Sun, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Si Chuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang, M.D.</last_name>
      <phone>+86 13808170699</phone>
    </contact>
    <investigator>
      <last_name>Wei Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opiate dependence</keyword>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Nucleus accumbens</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

